Filing Flows › Starling Oncology (STLN) › Specialty Pharmacy revenue
Starling Oncology (STLN) Specialty Pharmacy revenue by quarter
Starling Oncology's Specialty Pharmacy revenue was $109M in Q3 2026 (third quarter 2026), +11% from Q2 2026. Over the last 3 quarters it ranged from $87.5M (Q1 2026) to $109M (Q3 2026).
| Quarter | Specialty Pharmacy revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $109M | +11% | — |
| Q2 2026 | $98.6M | +13% | — |
| Q1 2026 | $87.5M | — | — |
Q3 2026 at a glance
Starling Oncology, Q3 2026: revenue $170M (+24% year over year), operating margin -1.8%, net loss $15.7M, operating cash flow $10.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Starling Oncology's Specialty Pharmacy revenue?
Starling Oncology's Specialty Pharmacy revenue was $109M in Q3 2026 (third quarter 2026), +11% from Q2 2026.
How has Starling Oncology's Specialty Pharmacy revenue changed?
Over the last 3 quarters it ranged from $87.5M (Q1 2026) to $109M (Q3 2026).